Articles

< Previous         Next >  
Metabolomic profiling reveals decreased serum cysteine levels during gestational diabetes mellitus progression
Mengyu Lai1,† , Jiaomeng Li2,† , Jiaying Yang1,† , Qingli Zhang2 , Yujia Gong1 , Yuhang Ma1 , Fang Fang1 , Na Li1 , Yingxiang Zhai2,3 , Tingting Shen1 , Yongde Peng1 , Jia Liu2,4,* , Yufan Wang1,*
1Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
2Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
3School of Pharmacy, Henan University, Kaifeng 475004, China
4School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310058, China
These authors contributed equally to this work
*Correspondence to:Jia Liu , Email:jia.liu@simm.ac.cn Yufan Wang , Email:yyffwang@sina.com
J Mol Cell Biol, Volume 16, Issue 3, March 2024, mjae010,  https://doi.org/10.1093/jmcb/mjae010
Keyword: gestational diabetes mellitus, metabolomics, cysteine

Gestational diabetes mellitus (GDM) is a pregnancy-related metabolic disorder associated with short-term and long-term adverse health outcomes, but its pathogenesis has not been clearly elucidated. Investigations of the dynamic changes in metabolomic markers in different trimesters may reveal the underlying pathophysiology of GDM progression. Therefore, in the present study, we analysed the metabolic profiles of 75 women with GDM and 75 women with normal glucose tolerance throughout the three trimesters. We found that the variation trends of 38 metabolites were significantly changed during GDM development. Specifically, longitudinal analyses revealed that cysteine (Cys) levels significantly decreased over the course of GDM progression. Further study showed that Cys alleviated GDM in female mice at gestational day 14.5, possibly by inhibiting phosphoenolpyruvate carboxykinase to suppress hepatic gluconeogenesis. Taken together, these findings suggest that the Cys metabolism pathway might play a crucial role in GDM and Cys supplementation represents a potential new treatment strategy for GDM patients.